MX2017014700A - Neoantigenos compartidos. - Google Patents
Neoantigenos compartidos.Info
- Publication number
- MX2017014700A MX2017014700A MX2017014700A MX2017014700A MX2017014700A MX 2017014700 A MX2017014700 A MX 2017014700A MX 2017014700 A MX2017014700 A MX 2017014700A MX 2017014700 A MX2017014700 A MX 2017014700A MX 2017014700 A MX2017014700 A MX 2017014700A
- Authority
- MX
- Mexico
- Prior art keywords
- tumor
- subjects
- specific
- population
- neoantigenic
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 9
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001162—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001196—Fusion proteins originating from gene translocation in cancer cells
- A61K39/001197—Breakpoint cluster region-abelson tyrosine kinase [BCR-ABL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se divulga aquí en un aspecto una composición farmacéutica que comprende una pluralidad de péptidos neoantigénicos y un portador farmacéuticamente aceptable, cada péptido neoantigénico que comprende un neoepítopo específico a tumor capaz de unirse a una proteína HLA en un sujeto, cada neoepítopo específico a tumor comprende una mutación específica a tumor presente en un tumor, en el que (a) la composición comprende péptidos neoantigénicos que comprenden mutaciones específicas a tumor presente en por lo menos 1% de lo sujetos en una población de sujetos que sufren de cáncer; (b) la composición comprende péptidos neoantigénicos que comprenden neoepítopos específicos a tumores que se unen a proteínas HLA presentes en por lo menos 5% de lo sujetos en la población; y (c) la composición comprende por lo menos un péptido neoantigénico capaz de provocar una respuesta inmunitaria contra un tumor presente en por lo menos 5% de los sujetos en la población de sujetos que sufren de cáncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562179877P | 2015-05-20 | 2015-05-20 | |
US201662389377P | 2016-02-23 | 2016-02-23 | |
PCT/US2016/033452 WO2016187508A2 (en) | 2015-05-20 | 2016-05-20 | Shared neoantigens |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017014700A true MX2017014700A (es) | 2018-08-15 |
Family
ID=56203902
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017014700A MX2017014700A (es) | 2015-05-20 | 2016-05-20 | Neoantigenos compartidos. |
MX2023005122A MX2023005122A (es) | 2015-05-20 | 2017-11-16 | Neoantigenos compartidos. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023005122A MX2023005122A (es) | 2015-05-20 | 2017-11-16 | Neoantigenos compartidos. |
Country Status (21)
Country | Link |
---|---|
US (2) | US10835585B2 (es) |
EP (1) | EP3297660A2 (es) |
JP (3) | JP6913032B2 (es) |
KR (1) | KR20180010229A (es) |
CN (2) | CN116196401A (es) |
AU (2) | AU2016264623B2 (es) |
BR (1) | BR112017024797A2 (es) |
CA (1) | CA2986235A1 (es) |
CL (2) | CL2017002945A1 (es) |
CO (1) | CO2017012835A2 (es) |
CR (3) | CR20200476A (es) |
EC (1) | ECSP17084137A (es) |
HK (2) | HK1251148A1 (es) |
IL (3) | IL302102A (es) |
MX (2) | MX2017014700A (es) |
MY (1) | MY190974A (es) |
PE (1) | PE20180670A1 (es) |
PH (1) | PH12017502321A1 (es) |
RU (2) | RU2020132040A (es) |
TW (2) | TWI806815B (es) |
WO (1) | WO2016187508A2 (es) |
Families Citing this family (165)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2738026C (en) | 2008-09-22 | 2017-01-24 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
DK3106463T6 (da) | 2008-10-22 | 2020-02-24 | Array Biopharma Inc | Pyrazolo[1,5-]pyrimidinforbindelse som trk-kinasehæmmer |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
HUE035337T2 (en) | 2010-05-20 | 2018-05-02 | Array Biopharma Inc | Macrocyclic compounds as TRK kinase inhibitors |
WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
CA2934073A1 (en) | 2013-12-20 | 2015-06-25 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
DK3699181T3 (da) | 2014-11-16 | 2023-03-20 | Array Biopharma Inc | Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat |
EP3234193B1 (en) | 2014-12-19 | 2020-07-15 | Massachusetts Institute of Technology | Molecular biomarkers for cancer immunotherapy |
EP3757211A1 (en) | 2014-12-19 | 2020-12-30 | The Broad Institute, Inc. | Methods for profiling the t-cell-receptor repertoire |
RU2020132040A (ru) | 2015-05-20 | 2020-10-12 | Те Брод Инститьют Инк. | Общие неоантигены |
TN2018000138A1 (en) | 2015-10-26 | 2019-10-04 | Array Biopharma Inc | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
IL259931B2 (en) | 2015-12-16 | 2024-02-01 | Gritstone Bio Inc | Identification of neo-antigens, preparation, and use |
WO2017124147A1 (en) * | 2016-01-19 | 2017-07-27 | The University Of Western Australia | Novel biomolecule conjugates and uses therefor |
US20170224796A1 (en) | 2016-02-05 | 2017-08-10 | Xeme Biopharma Inc. | Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System |
US11154597B2 (en) | 2016-03-24 | 2021-10-26 | Nantcell, Inc. | Sequence arrangements and sequences for neoepitope presentation |
SG11201808196UA (en) * | 2016-03-31 | 2018-10-30 | Neon Therapeutics Inc | Neoantigens and methods of their use |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
PE20181888A1 (es) | 2016-04-04 | 2018-12-11 | Loxo Oncology Inc | Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
CA3056212A1 (en) * | 2016-04-07 | 2017-10-12 | Bostongene Corporation | Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines |
WO2017190218A1 (en) * | 2016-05-06 | 2017-11-09 | University Health Network | Liquid-biopsy signatures for prostate cancer |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
EP3800189B1 (en) | 2016-05-18 | 2023-06-28 | Loxo Oncology, Inc. | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
WO2018094569A1 (zh) * | 2016-11-22 | 2018-05-31 | 深圳华大基因研究院 | 多肽及其应用 |
CN109952308B (zh) * | 2016-11-29 | 2022-09-23 | 武汉华大吉诺因生物科技有限公司 | 多肽及其应用 |
EP3548897A4 (en) * | 2016-12-01 | 2020-08-12 | Nantomics, LLC | PRESENTATION AND TREATMENT OF TUMOR ANTIGENICITY |
EP4119663A1 (en) | 2016-12-09 | 2023-01-18 | The Broad Institute, Inc. | Crispr effector system based diagnostics |
US11634486B2 (en) | 2016-12-23 | 2023-04-25 | Bluefin Biomedicine, Inc. | Anti-SEZ6L2 antibodies and antibody drug conjugates |
EP3568157A4 (en) * | 2017-01-13 | 2021-01-06 | National Research Council of Canada | METHOD FOR OPTIMIZING THE PEPTIDE IMMUNO-EPITOP BY GLYCOSYLATION, OPTIMIZED PEPTIDE THEREOF AND ITS USE FOR CONJUGATE VACCINES |
NZ755835A (en) | 2017-01-17 | 2023-12-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
WO2018136664A1 (en) * | 2017-01-18 | 2018-07-26 | Ichan School Of Medicine At Mount Sinai | Neoantigens and uses thereof for treating cancer |
WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
CN117224710A (zh) | 2017-02-01 | 2023-12-15 | 莫得纳特斯公司 | 编码活化致癌基因突变肽的免疫调节治疗性mrna组合物 |
US11771749B2 (en) | 2017-02-03 | 2023-10-03 | The Medical College Of Wisconsin, Inc. | KRAS peptide vaccine compositions and method of use |
CN106868133A (zh) * | 2017-02-24 | 2017-06-20 | 北京致成生物医学科技有限公司 | 一种监测肿瘤发生发展的产品及其应用 |
BR112019019087A2 (pt) | 2017-03-15 | 2020-05-12 | The Broad Institute, Inc. | Diagnóstico baseado em sistema efetor de crispr para detecção de vírus |
US11174515B2 (en) | 2017-03-15 | 2021-11-16 | The Broad Institute, Inc. | CRISPR effector system based diagnostics |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
CN108659114B (zh) * | 2017-04-01 | 2022-10-21 | 中国科学院广州生物医药与健康研究院 | 识别pasd1抗原短肽的tcr |
CA3061240C (en) | 2017-04-24 | 2024-01-16 | Nantcell, Inc. | Targeted neoepitope vectors and methods therefor |
WO2018208856A1 (en) | 2017-05-08 | 2018-11-15 | Gritstone Oncology, Inc. | Alphavirus neoantigen vectors |
WO2018209015A1 (en) * | 2017-05-10 | 2018-11-15 | University Of Connecticut | Dendritic cells as a novel delivery system for immunotherapy |
CA3063905A1 (en) * | 2017-05-16 | 2018-11-22 | The Johns Hopkins University | Manabodies and methods of using |
EP3641803A2 (en) | 2017-06-21 | 2020-04-29 | Transgene | Personalized vaccine |
ES2950653T3 (es) * | 2017-06-22 | 2023-10-11 | Neogap Therapeutics Ab | Método de expansión de linfocitos T y usos |
NL2019156B1 (en) * | 2017-06-30 | 2019-01-10 | Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum | Treatment of haematological malignancies |
WO2019004831A1 (en) * | 2017-06-30 | 2019-01-03 | Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) | TREATMENT OF HEMATOLOGICAL MALIGNANCIES |
CN107325171A (zh) * | 2017-07-06 | 2017-11-07 | 江苏迈健生物科技发展股份有限公司 | 抗原肽t790m‑7及其在制备治疗非小细胞肺癌的药物中的应用 |
CN107188955A (zh) * | 2017-07-06 | 2017-09-22 | 江苏迈健生物科技发展股份有限公司 | 抗原肽t790m‑3及其在制备治疗非小细胞肺癌的药物中的应用 |
SG11202000250PA (en) * | 2017-07-12 | 2020-02-27 | Nouscom Ag | A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers |
WO2019031939A2 (ko) * | 2017-08-10 | 2019-02-14 | 주식회사 굳티셀 | 암 치료를 위한 t 세포의 활성화 방법 |
CN111315390A (zh) * | 2017-09-05 | 2020-06-19 | 磨石肿瘤生物技术公司 | 用于t细胞疗法的新抗原鉴别 |
JP7320840B2 (ja) | 2017-09-11 | 2023-08-04 | 国立大学法人北海道大学 | 癌治療薬 |
AU2018342246A1 (en) * | 2017-09-29 | 2020-04-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing mutated p53 |
AU2018348165A1 (en) | 2017-10-10 | 2020-05-21 | Gritstone Bio, Inc. | Neoantigen identification using hotspots |
KR20200090855A (ko) | 2017-11-22 | 2020-07-29 | 그릿스톤 온콜로지, 인코포레이티드 | 신생항원에 대한 접합 에피토프 제시 감소 |
WO2019126186A1 (en) | 2017-12-18 | 2019-06-27 | Neon Therapeutics, Inc. | Neoantigens and uses thereof |
AU2019213047A1 (en) | 2018-01-29 | 2020-07-16 | Massachusetts Institute Of Technology | CRISPR effector system based diagnostics |
US20210038703A1 (en) * | 2018-02-15 | 2021-02-11 | National University Corporation Asahikawa Medical University | Cancer Antigen Peptide |
US20210238690A1 (en) * | 2018-04-26 | 2021-08-05 | Intellexon Gmbh | Hla-j and medical/diagnostic uses thereof |
CN108588201B (zh) * | 2018-05-11 | 2019-08-09 | 浙江省人民医院 | 一种结直肠癌西妥昔单抗耐药性痕量dna突变检测的方法及装置 |
EP4252759A3 (en) * | 2018-05-11 | 2023-11-08 | Memorial Sloan Kettering Cancer Center | T cell receptors targeting pik3ca mutations and uses thereof |
CN108588050B (zh) * | 2018-05-14 | 2021-06-25 | 北京艾克伦医疗科技有限公司 | Dna聚合酶以及核酸检测方法和试剂盒 |
CA3100974A1 (en) * | 2018-05-25 | 2020-11-28 | The Wistar Institute | Tumor-specific neoantigens and methods of using the same |
CN108728529B (zh) * | 2018-06-06 | 2020-08-04 | 青岛泱深生物医药有限公司 | Znf770基因在制备诊治子痫前期的产品中的应用 |
CN110577953B (zh) * | 2018-06-11 | 2024-02-20 | 深圳华大生命科学研究院 | 基因突变体及其应用 |
CN109142729B (zh) * | 2018-06-14 | 2021-04-23 | 郑州大学第一附属医院 | 一种肺癌标志物抗-hmgb3自身抗体及其应用 |
WO2019243272A1 (en) * | 2018-06-18 | 2019-12-26 | College De France | Ligand controling interaction between gags with their effector molecules and use thereof |
JP2021527655A (ja) * | 2018-06-19 | 2021-10-14 | ビオンテック ユーエス インコーポレイテッド | ネオ抗原およびそれらの使用 |
TW202015719A (zh) * | 2018-06-19 | 2020-05-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
GB201810358D0 (en) * | 2018-06-25 | 2018-08-08 | Univ College Cardiff Consultants Ltd | Cancer-specific t-cell receptors |
EP3827266A1 (en) | 2018-07-26 | 2021-06-02 | Frame Pharmaceuticals B.V. | Cancer vaccines for uterine cancer |
CA3106573A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for colorectal cancer |
US20220349010A1 (en) | 2018-07-26 | 2022-11-03 | Frame Pharmaceuticals B.V. | Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database |
US20210213116A1 (en) | 2018-07-26 | 2021-07-15 | Frame Pharmaceuticals B.V. | Cancer vaccines for kidney cancer |
CA3106574A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Arid1a, cdkn2a, kmt2b, kmt2d, tp53 and pten vaccines for cancer |
US20210162032A1 (en) | 2018-07-26 | 2021-06-03 | Frame Pharmaceuticals B.V. | Cancer vaccines for breast cancer |
TW202019955A (zh) | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
CN113728102A (zh) * | 2018-08-28 | 2021-11-30 | 罗氏创新中心哥本哈根有限公司 | 使用剪接调节化合物进行新抗原工程化 |
EP3846844A1 (en) * | 2018-09-05 | 2021-07-14 | Vaximm AG | Neoantigen targeting dna vaccine for combination therapy |
CN109022585A (zh) * | 2018-09-10 | 2018-12-18 | 路君 | Pbld基因在制备肾透明细胞癌诊断和预测预后药物中的应用 |
CA3113207A1 (en) * | 2018-09-20 | 2020-03-26 | Daiichi Sankyo Company, Limited | Treatment of her3-mutated cancer by administration of anti-her3 antibody-drug conjugate |
CN109207431B (zh) * | 2018-10-12 | 2021-10-15 | 武汉大学 | 一种抑制人癌基因STAT3的α亚型表达的方法 |
CN109486935A (zh) * | 2018-10-18 | 2019-03-19 | 中国医学科学院北京协和医院 | 作为骨质疏松症诊治靶标的aknad1基因 |
CN109321569B (zh) * | 2018-10-29 | 2022-04-12 | 迈杰转化医学研究(苏州)有限公司 | 一种引物探针组合物及其应用 |
CN111116754A (zh) * | 2018-10-30 | 2020-05-08 | 天津亨佳生物科技发展有限公司 | 一种针对egfr l858r基因突变的特异性tcr及其应用 |
WO2020092705A1 (en) * | 2018-10-31 | 2020-05-07 | University Of Virginia Patent Foundation | Self-assembling peptides and hydrogels |
CA3122378A1 (en) * | 2018-11-01 | 2020-05-07 | The Broad Institute, Inc. | Identification of pde3 modulator responsive cancers |
CN109504771A (zh) * | 2018-11-19 | 2019-03-22 | 北京大学深圳医院(北京大学深圳临床医学院) | Adcy2作为乳腺癌的分子标记物的应用 |
CN109438570B (zh) * | 2018-11-28 | 2021-07-20 | 生命谷(海南)生物科技股份有限公司 | 肿瘤相关基因fgfr3突变短肽及其应用 |
CN109371026A (zh) * | 2018-12-11 | 2019-02-22 | 宁夏医科大学总医院 | 一种环状RNA hsa_circACACB_035及其特异性扩增引物和应用 |
US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
CN111363816B (zh) * | 2018-12-26 | 2024-02-02 | 广州康立明生物科技股份有限公司 | 基于pax3和zic4基因的肺癌诊断试剂及试剂盒 |
CN109576362B (zh) * | 2018-12-28 | 2020-09-04 | 青岛泱深生物医药有限公司 | 阿尔茨海默诊治用标志物fam170a |
TW202043256A (zh) * | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
CN109504778B (zh) * | 2019-01-11 | 2021-11-09 | 复旦大学附属中山医院 | 一种基于表观修饰的5hmC多分子标志物及结直肠癌早期诊断模型 |
CN113905753A (zh) * | 2019-01-15 | 2022-01-07 | 康奈尔大学 | 重组粘蛋白和组合物以及其使用方法 |
CN112687352B (zh) * | 2019-01-29 | 2022-07-15 | 杭州纽安津生物科技有限公司 | 针对靶向药物依鲁替尼的多肽疫苗组合及其设计方法 |
WO2020168047A1 (en) * | 2019-02-13 | 2020-08-20 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Combination of t-cell therapy and targeted therapy for treating therapy-resistant melanoma with mutations in the braf gene |
JP2022521738A (ja) | 2019-02-20 | 2022-04-12 | ルビウス セラピューティクス, インコーポレイテッド | 負荷可能な抗原提示ポリペプチドを含む操作された赤血球系細胞および使用方法 |
CN109735624A (zh) * | 2019-03-14 | 2019-05-10 | 台州市立医院 | 基因标志物在甲状腺癌诊断中的应用 |
EP3941932A1 (en) * | 2019-03-21 | 2022-01-26 | Institute for Research in Biomedicine | Peptide inhibitors targeting the cxcl12/hmgb1 interaction and uses thereof |
IL266728B (en) * | 2019-05-19 | 2020-11-30 | Yeda Res & Dev | Identification of recurrent mutant neopeptides |
TW202110870A (zh) | 2019-05-30 | 2021-03-16 | 美商葛利史東腫瘤科技公司 | 經修飾之腺病毒 |
DE102019114735A1 (de) * | 2019-06-02 | 2020-12-03 | PMCR GmbH | HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen |
US11306122B2 (en) * | 2019-06-14 | 2022-04-19 | The United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods of inhibiting the binding of plasma IgG autoantibodies to serotonin 2A receptor |
CN114245745A (zh) * | 2019-06-20 | 2022-03-25 | 纪念斯隆-凯特琳癌症中心 | 靶向pik3ca突变的t细胞受体及其用途 |
CN110358827A (zh) * | 2019-07-09 | 2019-10-22 | 中国人民解放军第四军医大学 | Vmp1基因在病理诊断胶质母细胞瘤中的应用及其试剂盒的制备 |
CN110358831B (zh) * | 2019-07-11 | 2021-12-24 | 江苏医药职业学院 | 检测跨膜蛋白41a表达水平的试剂的应用和试剂盒 |
EP3997131A4 (en) * | 2019-07-12 | 2023-08-02 | The Regents of the University of California | CHEMICALLY DRIVEN MONOCLONAL ANTIBODY TARGETING |
EP3999547A4 (en) * | 2019-07-16 | 2023-07-12 | Washington University | ANTI-GRP78 ANTIBODIES AND METHODS OF USE THEREOF |
EP4003390A4 (en) * | 2019-07-30 | 2024-03-13 | Breakbio Corp | METHOD FOR TREATING SOLID TUMORS |
US11752197B2 (en) | 2019-08-12 | 2023-09-12 | Regeneron Pharmaceuticals, Inc. | Macrophage stimulating 1 receptor (MST1R) variants and uses thereof |
CN112402612B (zh) * | 2019-08-21 | 2023-05-26 | 苏州蓝马医疗技术有限公司 | 一种提高肿瘤新抗原疫苗免疫治疗疗效的方法 |
EP4055059A4 (en) * | 2019-11-06 | 2024-01-10 | Ohio State Innovation Foundation | TARGETING CIRCULAR PCMTD1 IN LEUKEMIA WITH P53 MUTATIONS AND/OR BCR/ABL FUSIONS |
KR20220098379A (ko) * | 2019-11-15 | 2022-07-12 | 그릿스톤 바이오, 인코포레이티드 | 공유 네오항원을 표적으로 하는 항원-결합 단백질 |
CA3165862A1 (en) | 2019-12-23 | 2021-07-01 | The Regents Of The University Of California | Stabilization of mhc complexes |
CN113117081A (zh) * | 2019-12-30 | 2021-07-16 | 上海海洋大学 | ZC3H12b基因或蛋白的用途及一种肝脏疾病动物模型的建立方法 |
EP4085130A4 (en) * | 2019-12-31 | 2024-04-10 | Elixirgen Therapeutics Inc | TEMPERATURE-BASED TRANSIENT DELIVERY OF NUCLEIC ACIDS AND PROTEINS TO CELLS AND TISSUES |
CN111116728B (zh) * | 2020-01-13 | 2021-04-27 | 郑州大学 | 肿瘤特异性抗原ctl表位肽及其应用 |
US20230080534A1 (en) * | 2020-01-21 | 2023-03-16 | Shanghai Biotroy Biotechnique Co., Ltd. | Semg2 antibody and use thereof |
WO2021168355A1 (en) * | 2020-02-20 | 2021-08-26 | Gritstone Bio, Inc. | Antigen-binding proteins targeting kklc-1 shared antigen |
CN111303268B (zh) * | 2020-03-10 | 2021-08-27 | 江苏兰恩生物治疗技术研究院有限公司 | 子宫肌瘤新抗原、其应用和子宫肌瘤疫苗 |
CN114315964B (zh) * | 2020-03-18 | 2023-06-13 | 北京鼎成肽源生物技术有限公司 | 一种输卵管癌靶标抗原组合、输卵管癌靶标抗原刺激培养的ctl细胞及其应用 |
CN113817740A (zh) * | 2020-06-19 | 2021-12-21 | 中国科学院化学研究所 | 一种核酸适配体识别并结合ptprf及其相关功能的应用研究 |
CN111718405B (zh) * | 2020-06-30 | 2022-09-13 | 青岛海兰深生物科技有限公司 | 一种检测抗胰腺癌天然抗体的组合物、试剂盒和方法 |
WO2022000399A1 (en) * | 2020-07-02 | 2022-01-06 | The Johns Hopkins University | Methylated markers for accurate detection of primary central nervous system and systemic diffuse large b cell lymphoma |
CN116438308A (zh) | 2020-08-06 | 2023-07-14 | 磨石生物公司 | 多表位疫苗盒 |
KR20230086765A (ko) | 2020-10-13 | 2023-06-15 | 얀센 바이오테크 인코포레이티드 | 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법 |
US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
JP2023551204A (ja) * | 2020-11-20 | 2023-12-07 | シンク・セラピューティクス・インコーポレイテッド | 最適化ペプチドワクチンの組成物および方法 |
WO2022140759A2 (en) * | 2020-12-23 | 2022-06-30 | Janssen Biotech, Inc. | Neoantigen peptide mimics |
CN112666358A (zh) * | 2021-01-14 | 2021-04-16 | 深圳裕康医学检验实验室 | 一种使用外周血检测抗原免疫原性的方法 |
CN113150140B (zh) * | 2021-01-25 | 2022-11-04 | 山西农业大学 | 一种sox6二价纳米抗体及其应用 |
WO2022179568A1 (en) * | 2021-02-25 | 2022-09-01 | Westlake Therapeutics (Hangzhou) Co., Limited | Neoantigenic peptide and its use for treating braf gene mutation related diseases |
AU2022240549A1 (en) * | 2021-03-16 | 2023-10-05 | Shanghai Biotroy Biotechnique Co., Ltd | Semenogelin neutralizing antibody and epitope and application thereof |
CN113667002B (zh) * | 2021-03-24 | 2023-03-28 | 深圳市新靶向生物科技有限公司 | 一种与肺癌驱动基因突变相关的抗原肽及其应用 |
CN113321724B (zh) * | 2021-03-24 | 2022-02-01 | 深圳市新靶向生物科技有限公司 | 一种与食道癌驱动基因突变相关的抗原肽及其应用 |
CN114163512A (zh) * | 2021-03-24 | 2022-03-11 | 深圳市新靶向生物科技有限公司 | 一种与肝癌驱动基因突变相关的抗原肽组合及其应用 |
US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
IL282814A (en) * | 2021-04-29 | 2022-11-01 | Yeda Res & Dev | T-cell receptors against recurrent ras-derived neoantigens |
CA3214450A1 (en) | 2021-04-30 | 2022-11-03 | Tigen Pharma Sa | Single vessel expansion of lymphocytes |
CN113527464A (zh) * | 2021-07-19 | 2021-10-22 | 新景智源生物科技(苏州)有限公司 | 识别mboat2的tcr |
CN113721030B (zh) * | 2021-08-30 | 2024-02-13 | 河南中医药大学 | 用于桥本甲状腺炎不同证候特征性自身抗体检测的生物标志物及其应用 |
CN114085281A (zh) * | 2021-10-15 | 2022-02-25 | 北京臻知医学科技有限责任公司 | 一种肿瘤抗原表位肽及其多聚体和应用 |
CN114085282A (zh) * | 2021-10-15 | 2022-02-25 | 北京臻知医学科技有限责任公司 | 一种肿瘤新生抗原表位肽Pep6及其多聚体和应用 |
WO2023081655A1 (en) * | 2021-11-02 | 2023-05-11 | Fred Hutchinson Cancer Center | T cell immunotherapy for hematologic malignancies having an sf3b1 mutation |
KR20230068628A (ko) | 2021-11-11 | 2023-05-18 | 의료법인 명지의료재단 | Kras 특이적 활성화 t 세포 유도용 항원 조성물 |
KR20230068627A (ko) | 2021-11-11 | 2023-05-18 | 의료법인 명지의료재단 | Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법 |
CN114177274A (zh) * | 2021-12-13 | 2022-03-15 | 中国医学科学院微循环研究所 | Tdrd10蛋白及其编码基因在制备肿瘤治疗药物中的应用、及肿瘤治疗药物 |
WO2023114430A1 (en) * | 2021-12-16 | 2023-06-22 | The Johns Hopkins University | Manabodies targeting p53 tumor antigens and methods of using |
KR20230101287A (ko) | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
KR20230101283A (ko) | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
KR20230101285A (ko) | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
KR20230101286A (ko) | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
KR20230101284A (ko) | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
WO2023150788A2 (en) * | 2022-02-07 | 2023-08-10 | Ubiquitx | Beta-catenin protein degradation |
CN117586344A (zh) * | 2022-08-12 | 2024-02-23 | 上海交通大学医学院附属瑞金医院 | 靶向flt3-d835突变的抗原肽及其在肿瘤免疫治疗中的应用 |
WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
CN115651984B (zh) * | 2022-10-20 | 2023-04-14 | 山东大学 | 一种生物标志物在评价肿瘤紫杉类化疗耐药性的应用 |
CN116948004B (zh) * | 2023-09-13 | 2023-11-21 | 成都朗谷生物科技股份有限公司 | 针对ctnnb1基因h36p突变的肿瘤新抗原多肽及其应用 |
CN117567591B (zh) * | 2024-01-11 | 2024-04-26 | 中国人民解放军总医院 | 一种用于研究Tmem247蛋白的新型鼠源Tmem247抗体制备方法和应用 |
Family Cites Families (278)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3870790A (en) | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
US4210644A (en) | 1978-02-23 | 1980-07-01 | The Johns Hopkins University | Male contraception |
US4226859A (en) | 1979-06-07 | 1980-10-07 | Velsicol Chemical Corporation | Pyridyl esters of N-alkylidene-substituted phosphor- and phosphonamidic acids |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
ZA825384B (en) | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US7767449B1 (en) | 1981-12-24 | 2010-08-03 | Health Research Incorporated | Methods using modified vaccinia virus |
US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
ATE66143T1 (de) | 1985-01-11 | 1991-08-15 | Abbott Lab | Feste zubereitung mit langsamer freisetzung. |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US4743249A (en) | 1986-02-14 | 1988-05-10 | Ciba-Geigy Corp. | Dermal and transdermal patches having a discontinuous pattern adhesive layer |
US4844893A (en) | 1986-10-07 | 1989-07-04 | Scripps Clinic And Research Foundation | EX vivo effector cell activation for target cell killing |
US4906169A (en) | 1986-12-29 | 1990-03-06 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
US5023084A (en) | 1986-12-29 | 1991-06-11 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
US4816540A (en) | 1987-06-12 | 1989-03-28 | Yasuhiko Onishi | Cationic graft-copolymer |
US5422119A (en) | 1987-09-24 | 1995-06-06 | Jencap Research Ltd. | Transdermal hormone replacement therapy |
US5035891A (en) | 1987-10-05 | 1991-07-30 | Syntex (U.S.A.) Inc. | Controlled release subcutaneous implant |
CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
US5906936A (en) | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
CA2005291C (en) | 1988-12-30 | 1999-01-26 | Beverly Dale | Feline infectious peritonitis virus diagnostic tools |
US6780407B1 (en) | 1989-03-08 | 2004-08-24 | Aventis Pasteur | Pox virus comprising DNA sequences encoding CEA and B7 antigen |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US4973468A (en) | 1989-03-22 | 1990-11-27 | Cygnus Research Corporation | Skin permeation enhancer compositions |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
DK0452457T3 (da) | 1989-11-03 | 1998-03-02 | Univ Vanderbilt | Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
US5198223A (en) | 1990-10-29 | 1993-03-30 | Alza Corporation | Transdermal formulations, methods and devices |
US6309647B1 (en) | 1999-07-15 | 2001-10-30 | Aventis Pasteur | Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants |
US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
US6277558B1 (en) | 1990-11-30 | 2001-08-21 | Kansas University Medical Center | α-3 chain type IV collagen polynucleotides |
AU1588092A (en) | 1991-02-22 | 1992-09-15 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Transmission blocking vaccine against malaria |
US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
US5756101A (en) | 1991-07-01 | 1998-05-26 | Pasteur Merieux Serums Et Vaccins | Malaria recombinant poxvirus |
US6753162B1 (en) | 1991-03-07 | 2004-06-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
US6004811A (en) | 1991-03-07 | 1999-12-21 | The Massachussetts General Hospital | Redirection of cellular immunity by protein tyrosine kinase chimeras |
EP0575491B1 (en) | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
US5766597A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Malaria recombinant poxviruses |
US5851828A (en) | 1991-03-07 | 1998-12-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
IE920716A1 (en) | 1991-03-07 | 1992-09-09 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
US5912170A (en) | 1991-03-07 | 1999-06-15 | The General Hospital Corporation | Redirection of cellular immunity by protein-tyrosine kinase chimeras |
US5843728A (en) | 1991-03-07 | 1998-12-01 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
AU4528493A (en) | 1992-06-04 | 1994-01-04 | Regents Of The University Of California, The | In vivo gene therapy with intron-free sequence of interest |
US9340577B2 (en) | 1992-08-07 | 2016-05-17 | Epimmune Inc. | HLA binding motifs and peptides and their uses |
US6991797B2 (en) | 1993-07-02 | 2006-01-31 | Statens Serum Institut | M. tuberculosis antigens |
WO1995030018A2 (en) | 1994-04-29 | 1995-11-09 | Immuno Aktiengesellschaft | Recombinant poxviruses with foreign polynucleotides in essential regions |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US6924128B2 (en) | 1994-12-06 | 2005-08-02 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
US5849303A (en) | 1995-06-07 | 1998-12-15 | American Home Products Corporation | Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection |
US5820869A (en) | 1995-06-07 | 1998-10-13 | American Home Products Corporation | Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US5705190A (en) | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
FR2750865B1 (fr) | 1996-06-27 | 1998-12-04 | Rhone Merieux | Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2 |
US6090393A (en) | 1996-07-03 | 2000-07-18 | Merial | Recombinant canine adenoviruses, method for making and uses thereof |
US6156567A (en) | 1996-07-03 | 2000-12-05 | Merial | Truncated transcriptionally active cytomegalovirus promoters |
FR2751227B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives |
US7198784B2 (en) | 1996-10-17 | 2007-04-03 | Oxford Biomedica (Uk) Limited | Retroviral vectors |
IL129017A0 (en) | 1996-10-17 | 2000-02-17 | Oxford Biomedica Ltd | Retroviral vectors |
US7255862B1 (en) | 1996-11-14 | 2007-08-14 | Connaught Technology Corporation | ALVAC/FIV constructs |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
EP0973928B1 (en) | 1997-03-11 | 2010-05-05 | Regents Of The University Of Minnesota | Dna-based transposon system for the introduction of nucleic acid into dna of a cell |
US6004777A (en) | 1997-03-12 | 1999-12-21 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
US5990091A (en) | 1997-03-12 | 1999-11-23 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
EP1015619A1 (en) | 1997-09-19 | 2000-07-05 | The Trustees Of The University Of Pennsylvania | Methods and cell line useful for production of recombinant adeno-associated viruses |
CA2303768C (en) | 1997-09-19 | 2009-11-24 | The Trustees Of The University Of Pennsylvania | Methods and vector constructs useful for production of recombinant aav |
GB9720465D0 (en) | 1997-09-25 | 1997-11-26 | Oxford Biomedica Ltd | Dual-virus vectors |
US6346415B1 (en) | 1997-10-21 | 2002-02-12 | Targeted Genetics Corporation | Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
FR2775601B1 (fr) | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
US6953690B1 (en) | 1998-03-20 | 2005-10-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
AU4800999A (en) | 1998-07-28 | 2000-02-21 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing drug at target site in intestine |
WO2000020587A2 (en) | 1998-10-05 | 2000-04-13 | Ludwig Institute For Cancer Research | Cancer associated antigens and uses therefor |
CA2348382C (en) | 1998-11-10 | 2013-09-17 | The University Of North Carolina At Chapel Hill | Chimeric parvovirus vectors and methods of making and administering the same |
US7160682B2 (en) | 1998-11-13 | 2007-01-09 | Regents Of The University Of Minnesota | Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell |
US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US6893865B1 (en) | 1999-04-28 | 2005-05-17 | Targeted Genetics Corporation | Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles |
NO309798B1 (no) * | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US6793926B1 (en) | 1999-05-27 | 2004-09-21 | Genovo, Inc. | Methods for production of a recombinant adeno-associated virus |
US6537540B1 (en) | 1999-05-28 | 2003-03-25 | Targeted Genetics Corporation | Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders |
AU5898400A (en) | 1999-06-29 | 2001-01-31 | Epimmune, Inc. | Hla binding peptides and their uses |
US6955808B2 (en) | 1999-09-24 | 2005-10-18 | Uab Research Foundation | Capsid-modified recombinant adenovirus and methods of use |
US7115391B1 (en) | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
CA2397998A1 (en) | 2000-01-28 | 2001-08-02 | Statens Serum Institut | Hiv peptides and nucleic acids encoding them for diagnosis and control of hiv infection |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
JP2004500095A (ja) | 2000-02-24 | 2004-01-08 | エクサイト セラピーズ, インコーポレイテッド | 細胞の同時の刺激および濃縮 |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
WO2001068820A1 (en) | 2000-03-14 | 2001-09-20 | Anton Mayr | Altered strain of the modified vaccinia virus ankara (mva) |
US6686184B1 (en) | 2000-05-25 | 2004-02-03 | President And Fellows Of Harvard College | Patterning of surfaces utilizing microfluidic stamps including three-dimensionally arrayed channel networks |
GB0024550D0 (es) | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
US7097842B2 (en) | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
US7445924B2 (en) | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
NZ524661A (en) | 2000-11-23 | 2005-03-24 | Bavarian Nordic As | Modified vaccinia ankara virus variant |
US7628980B2 (en) | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
US6923973B1 (en) | 2001-02-22 | 2005-08-02 | Board Of Regents, The University Of Texas System | Peptide and DNA immunization against Coccidioides immitis infections |
US20030104008A1 (en) | 2001-04-06 | 2003-06-05 | Loosmore Sheena May | Recombinant vaccine against west nile virus |
AU2002322280A1 (en) * | 2001-06-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
PT1421115E (pt) | 2001-08-31 | 2005-07-29 | Avidex Ltd | Receptor de celulas t soluvel |
EP2287186B1 (en) | 2001-09-06 | 2014-12-31 | Agensys, Inc. | Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer |
US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
WO2003057171A2 (en) | 2002-01-03 | 2003-07-17 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
NZ536420A (en) | 2002-04-12 | 2008-04-30 | Medarex Inc | Methods of treatment using CTLA-4 antibodies |
EP1839672A3 (en) | 2002-04-19 | 2007-11-21 | Bavarian Nordic A/S | Modified vaccinia virus Ankara for the vaccination of neonates |
WO2003089618A2 (en) | 2002-04-22 | 2003-10-30 | Regents Of The University Of Minnesota | Transposon system and methods of use |
US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
CA2488382A1 (en) | 2002-06-05 | 2003-12-18 | Case Western Reserve University | Methods and compositions for detecting cancers |
JP2005529187A (ja) | 2002-06-13 | 2005-09-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 同種抗原の特定方法、ならびに癌治療および移植へのその使用 |
JP2006507921A (ja) | 2002-06-28 | 2006-03-09 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 流体分散のための方法および装置 |
GB0220467D0 (en) | 2002-09-03 | 2002-10-09 | Oxford Biomedica Ltd | Composition |
US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
DE60329201D1 (de) | 2002-09-20 | 2009-10-22 | Chugai Pharmaceutical Co Ltd | Substituierte wt1-peptide |
US20070224201A1 (en) * | 2002-10-02 | 2007-09-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7569664B2 (en) | 2002-10-09 | 2009-08-04 | Immunocore Limited | Single chain recombinant T cell receptors |
ATE432290T1 (de) | 2002-11-09 | 2009-06-15 | Immunocore Ltd | T ZELL REZEPTOR ßDISPLAYß |
CA2511625A1 (en) | 2002-12-23 | 2004-07-15 | City Of Hope | Modified vaccinia ankara expressing p53 in cancer immunotherapy |
GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
US20060078893A1 (en) | 2004-10-12 | 2006-04-13 | Medical Research Council | Compartmentalised combinatorial chemistry by microfluidic control |
US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
EP3616781A1 (en) | 2003-04-10 | 2020-03-04 | President and Fellows of Harvard College | Formation and control of fluidic species |
CA2522812C (en) | 2003-04-18 | 2012-08-21 | Idm Pharma, Inc. | Hla-a2 tumor associated antigen peptides and compositions |
US7985739B2 (en) | 2003-06-04 | 2011-07-26 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced sleeping beauty transposon system and methods for using the same |
MXPA06000942A (es) | 2003-07-24 | 2006-03-30 | Merial Ltd | Nuevas formulaciones de vacunas. |
CN104069784B (zh) | 2003-08-27 | 2017-01-11 | 哈佛大学 | 流体物种的电子控制 |
US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
US7084247B2 (en) | 2004-03-11 | 2006-08-01 | Peptimmune, Inc. | Identification of self and non-self antigens implicated in autoimmune diseases |
WO2005092928A1 (en) | 2004-03-11 | 2005-10-06 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination |
US20050221339A1 (en) | 2004-03-31 | 2005-10-06 | Medical Research Council Harvard University | Compartmentalised screening by microfluidic control |
NZ550810A (en) | 2004-05-19 | 2009-05-31 | Immunocore Ltd | High affinity NY-ESO T cell receptor |
NZ550815A (en) | 2004-05-19 | 2009-04-30 | Immunocore Ltd | Method of improving T cell receptors |
US20060008468A1 (en) | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
JP5563194B2 (ja) | 2004-06-29 | 2014-07-30 | イムノコア リミテッド | 改変t細胞レセプターを発現する細胞 |
JP4772045B2 (ja) | 2004-07-16 | 2011-09-14 | アメリカ合衆国 | Cmv/r核酸コンストラクトを含むaidsに対するワクチン |
US7220549B2 (en) | 2004-12-30 | 2007-05-22 | Helicos Biosciences Corporation | Stabilizing a nucleic acid for nucleic acid sequencing |
CA2597928A1 (en) | 2005-02-16 | 2006-08-24 | Lentigen Corporation | Lentiviral vectors and their use |
EP2248578B1 (en) | 2005-03-04 | 2012-06-06 | President and Fellows of Harvard College | Method for forming multiple emulsions |
US7283337B2 (en) | 2005-03-04 | 2007-10-16 | Headway Technologies, Inc. | Abutted exchange bias design for sensor stabilization |
UY29460A1 (es) | 2005-04-08 | 2006-11-30 | Noxxon Pharma Ag | Acidos nucleicos de union a ghrelin |
CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
WO2006125962A2 (en) | 2005-05-25 | 2006-11-30 | Medigene Limited | T cell receptors which specifically bind to vygfvracl-hla-a24 |
WO2007015540A1 (ja) | 2005-08-03 | 2007-02-08 | Medical And Biological Laboratories Co., Ltd. | 細胞傷害性t細胞エピトープペプチド及びその用途 |
DK2578685T3 (da) | 2005-08-23 | 2019-06-03 | Univ Pennsylvania | Rna indeholende modificerede nukleosider og fremgangsmåder til anvendelse deraf |
US20070112754A1 (en) | 2005-11-15 | 2007-05-17 | Honeywell International Inc. | Method and apparatus for identifying data of interest in a database |
JP2009536313A (ja) | 2006-01-11 | 2009-10-08 | レインダンス テクノロジーズ, インコーポレイテッド | ナノリアクターの形成および制御において使用するマイクロ流体デバイスおよび方法 |
CA2640024A1 (en) | 2006-01-27 | 2007-08-09 | President And Fellows Of Harvard College | Fluidic droplet coalescence |
US8793895B2 (en) | 2006-02-10 | 2014-08-05 | Praxair Technology, Inc. | Lyophilization system and method |
WO2007101227A2 (en) | 2006-02-27 | 2007-09-07 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Identification and use of novopeptides for the treatment of cancer |
US7919079B2 (en) | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
EP2530168B1 (en) | 2006-05-11 | 2015-09-16 | Raindance Technologies, Inc. | Microfluidic Devices |
US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
EP2390356A1 (en) | 2006-06-02 | 2011-11-30 | GlaxoSmithKline Biologicals S.A. | Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the FASLG gene |
US20100035973A1 (en) | 2006-07-17 | 2010-02-11 | Nationwide Children's Hospital, Inc. | Disruption of programmed death 1 (pd-1) ligand to adjuvant adeno-associated virus vector vaccines |
WO2008039818A2 (en) | 2006-09-26 | 2008-04-03 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified t cell receptors and related materials and methods |
WO2008038002A2 (en) | 2006-09-29 | 2008-04-03 | Medigene Limited | T cell therapies |
US8349167B2 (en) | 2006-12-14 | 2013-01-08 | Life Technologies Corporation | Methods and apparatus for detecting molecular interactions using FET arrays |
US8262900B2 (en) | 2006-12-14 | 2012-09-11 | Life Technologies Corporation | Methods and apparatus for measuring analytes using large scale FET arrays |
EP2127671B1 (en) | 2007-02-07 | 2016-09-14 | Nec Corporation | Therapeutic agent for cancer |
WO2008109075A2 (en) | 2007-03-05 | 2008-09-12 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to ctla-4 antagonists |
AU2008231072B2 (en) | 2007-03-22 | 2013-08-01 | The Regents Of The University Of Colorado | Method of preparing an immunologically-active adjuvant-bound dried vaccine composition |
CA2689536A1 (en) | 2007-05-31 | 2008-12-04 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | P53 peptide vaccine |
ES2591281T3 (es) | 2007-07-12 | 2016-11-25 | Gitr, Inc. | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
RU2488592C2 (ru) | 2007-08-08 | 2013-07-27 | Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем | Пептиды направленного действия на vegfr-1/nrp-1 |
KR20100056523A (ko) | 2007-09-11 | 2010-05-27 | 몬도바이오테크 래보래토리즈 아게 | 치료제로서의 grf-1 (1-29) 및 코르티코트로핀-방출 인자의 용도 |
EP3192521B1 (en) | 2007-10-25 | 2020-09-16 | Toray Industries, Inc. | Immune response inducer |
WO2009086472A2 (en) | 2007-12-28 | 2009-07-09 | John Wayne Cancer Institute | Use of methylation status of mint loci and tumor-related genes as a marker for melanoma and breast cancer |
CN101970051A (zh) | 2007-12-31 | 2011-02-09 | 纳诺科尔治疗公司 | 用于治疗心力衰竭的rna干扰 |
US20110097312A1 (en) | 2008-02-15 | 2011-04-28 | Board Of Regents, The University Of Texas System | Anti-cancer vaccines |
WO2009126306A2 (en) | 2008-04-10 | 2009-10-15 | Cell Signaling Technology, Inc. | Compositions and methods for detecting egfr mutations in cancer |
AU2009292996B2 (en) | 2008-09-22 | 2015-04-23 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters |
JP2012505904A (ja) | 2008-10-17 | 2012-03-08 | ジェネンテック, インコーポレイテッド | 治療方法 |
US20100137143A1 (en) | 2008-10-22 | 2010-06-03 | Ion Torrent Systems Incorporated | Methods and apparatus for measuring analytes |
AU2009317161B2 (en) | 2008-11-24 | 2014-09-11 | Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt Gmbh | High affinity T cell receptor and use thereof |
PT2413956T (pt) | 2009-04-02 | 2016-12-30 | Vaxon Biotech | Identificação, optimização e utilização de epitopos crípticos hla-a24 para imunoterapia |
CN102741280B (zh) | 2009-10-30 | 2015-12-02 | 诺维信生物制药丹麦公司 | 白蛋白变体 |
PE20121359A1 (es) | 2009-12-10 | 2012-10-15 | Merck Patent Gmbh | Composicion farmaceutica que comprende oligopeptidos |
US9023802B2 (en) | 2009-12-14 | 2015-05-05 | Immatics Biotechnologies Gmbh | HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
US10837883B2 (en) | 2009-12-23 | 2020-11-17 | Bio-Rad Laboratories, Inc. | Microfluidic systems and methods for reducing the exchange of molecules between droplets |
GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
TW201138782A (en) | 2010-04-26 | 2011-11-16 | Besins Healthcare Lu Sarl | Low-oil pharmaceutical emulsion compositions comprising progestogen |
US9115402B2 (en) | 2010-05-14 | 2015-08-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of identifying tumor specific neoantigens |
US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
CN102946907A (zh) | 2010-05-28 | 2013-02-27 | 牛津生物医学(英国)有限公司 | 慢病毒载体向脑的递送 |
EP2575803B1 (en) | 2010-06-02 | 2017-07-26 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
JP2013536240A (ja) | 2010-08-24 | 2013-09-19 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | インターロイキン−13受容体α2ペプチド脳がんワクチン |
CN106220739A (zh) | 2010-12-09 | 2016-12-14 | 宾夕法尼亚大学董事会 | 嵌合抗原受体‑修饰的t细胞治疗癌症的用途 |
AU2012206487A1 (en) | 2011-01-14 | 2013-07-18 | Genefirst Limited | Methods, compositions, and kits for determining the presence/absence of a variant nucleic acid sequence |
EP2478915A1 (en) | 2011-01-24 | 2012-07-25 | Genticel | CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses |
WO2012109600A2 (en) | 2011-02-11 | 2012-08-16 | Raindance Technologies, Inc. | Methods for forming mixed droplets |
WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
US20120295960A1 (en) | 2011-05-20 | 2012-11-22 | Oxford Biomedica (Uk) Ltd. | Treatment regimen for parkinson's disease |
FI3892295T3 (fi) | 2011-05-24 | 2023-05-10 | BioNTech SE | Yksilöityjä rokotteita syöpää varten |
WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
CN103906848B (zh) | 2011-08-18 | 2016-03-02 | 雀巢产品技术援助有限公司 | 用于检测等位变体的组合物和方法 |
WO2013036201A1 (en) | 2011-09-06 | 2013-03-14 | Agency For Science, Technology And Research | Polypeptide vaccine |
CA2848209C (en) | 2011-09-15 | 2021-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
WO2013040371A2 (en) | 2011-09-16 | 2013-03-21 | Baylor College Of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
WO2013086464A1 (en) | 2011-12-07 | 2013-06-13 | The Broad Institute, Inc. | Markers associated with chronic lymphocytic leukemia prognosis and progression |
US20130210014A1 (en) | 2012-02-10 | 2013-08-15 | Jeff Sharman | Method for determining the prognosis and therapeutic response in chronic lymphocytic leukemia (cll) patients |
WO2013123031A2 (en) | 2012-02-15 | 2013-08-22 | Veridex, Llc | Highly sensitive method for detecting low frequency mutations |
US20150359864A1 (en) | 2012-03-09 | 2015-12-17 | Oncotherapy Science, Inc. | Pharmaceutical composition containing peptides |
NZ702108A (en) | 2012-05-03 | 2016-09-30 | Hutchinson Fred Cancer Res | Enhanced affinity t cell receptors and methods for making the same |
PE20142406A1 (es) | 2012-05-04 | 2015-01-23 | Pfizer | Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna |
US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
MA37681B2 (fr) | 2012-05-25 | 2020-07-29 | Cellectis | Procédés pour modifier des lymphocytes t résistants allogéniques et immunosuppresseurs pour l'immunothérapie |
WO2013188831A1 (en) | 2012-06-15 | 2013-12-19 | Adaptive Biotechnologies Corporation | Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set |
JP2015533473A (ja) | 2012-07-12 | 2015-11-26 | ペルシミューン,インコーポレイテッド | 個別のがんワクチン及び適応免疫細胞療法 |
PL2872646T3 (pl) | 2012-07-12 | 2018-03-30 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Sposoby przewidywania czasu przeżycia i responsywności na leczenie pacjenta cierpiącego na nowotwór lity z sygnaturą przynajmniej 7 genów |
CN104507537A (zh) | 2012-07-13 | 2015-04-08 | 宾夕法尼亚大学董事会 | 用于调节car t细胞的组合物和方法 |
US20150191524A1 (en) | 2012-07-27 | 2015-07-09 | The Board Of Trustees Of The University Of Illinoi | Engineering t cell receptors |
EP2897631A4 (en) | 2012-08-31 | 2016-10-05 | Univ Virginia Patent Found | TARGET PEPTIDES FOR IMMUNOTHERAPY AND DIAGNOSIS |
EP2898096B1 (en) | 2012-09-21 | 2024-02-14 | The Broad Institute, Inc. | Methods for labeling of rnas |
ES2824024T3 (es) | 2012-10-10 | 2021-05-11 | Sangamo Therapeutics Inc | Compuestos modificadores de células T y usos de los mismos |
WO2014056986A1 (en) | 2012-10-11 | 2014-04-17 | Universitat De Barcelona | Method to predict the clinical evolution of a patient suffering of chronic lymphocytic leukemia (cll) |
WO2014085802A1 (en) | 2012-11-30 | 2014-06-05 | The Broad Institute, Inc. | High-throughput dynamic reagent delivery system |
GB2508414A (en) | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
CN105102467B (zh) | 2013-02-07 | 2019-01-22 | 新泽西鲁特格斯州立大学 | 高度选择性核酸扩增引物 |
IL298125A (en) | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
EP3628322A1 (en) | 2013-03-01 | 2020-04-01 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Cd8+ t cells that also express pd-1 and/or tim-3 for the treatment of cancer |
EP2961415B1 (en) | 2013-03-01 | 2021-01-06 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of producing enriched populations of tumor-reactive t cells from tumor |
US10176294B2 (en) | 2013-03-15 | 2019-01-08 | The Broad Institute, Inc. | Accurate typing of HLA through exome sequencing |
BR112015025460B1 (pt) | 2013-04-07 | 2024-01-02 | The Broad Institute, Inc. | Método para a produção de uma vacina personalizada contra a neoplasia para um indivíduo diagnosticado como tendo uma neoplasia, vacina personalizada e uso da mesma |
US20160215042A1 (en) | 2013-04-19 | 2016-07-28 | The Brigham And Women's Hospital, Inc. | Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins |
WO2014184744A1 (en) | 2013-05-13 | 2014-11-20 | Cellectis | Methods for engineering highly active t cell for immunotherapy |
US9890393B2 (en) | 2013-05-29 | 2018-02-13 | Cellectis | Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system |
EP3293275B1 (en) * | 2013-06-06 | 2021-08-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms |
WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
KR102429859B1 (ko) | 2013-12-06 | 2022-08-04 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생물 백신을 위한 제형 |
CA2934073A1 (en) | 2013-12-20 | 2015-06-25 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
DK3152569T3 (da) | 2014-06-05 | 2020-08-17 | Aimm Therapeutics Bv | Midler og fremgangsmåder til bestemmelse af t-cellegenkendelse |
PT3198026T (pt) | 2014-08-07 | 2020-01-16 | Pharmassist Ltd | Método de determinação do estado mutacional de pik3ca numa amostra |
EP3198031A1 (en) | 2014-09-22 | 2017-08-02 | Dana Farber Cancer Institute, Inc. | Use of clonal evolution analysis for ibrutinib resistance in chronic lymphocytic leukemia patients |
EP3757211A1 (en) | 2014-12-19 | 2020-12-30 | The Broad Institute, Inc. | Methods for profiling the t-cell-receptor repertoire |
EP3234193B1 (en) | 2014-12-19 | 2020-07-15 | Massachusetts Institute of Technology | Molecular biomarkers for cancer immunotherapy |
WO2016164833A1 (en) * | 2015-04-08 | 2016-10-13 | Nantomics, Llc | Cancer neoepitopes |
WO2016172722A1 (en) * | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
WO2016183042A1 (en) | 2015-05-10 | 2016-11-17 | Quandx Inc. | Ultra sensitive probes for detection of nucleic acid |
RU2020132040A (ru) | 2015-05-20 | 2020-10-12 | Те Брод Инститьют Инк. | Общие неоантигены |
TW202241500A (zh) | 2015-06-09 | 2022-11-01 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
SG11201808196UA (en) | 2016-03-31 | 2018-10-30 | Neon Therapeutics Inc | Neoantigens and methods of their use |
WO2017184590A1 (en) | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Improved hla epitope prediction |
WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
-
2016
- 2016-05-20 RU RU2020132040A patent/RU2020132040A/ru unknown
- 2016-05-20 PE PE2017002446A patent/PE20180670A1/es unknown
- 2016-05-20 BR BR112017024797-6A patent/BR112017024797A2/pt active Search and Examination
- 2016-05-20 CR CR20200476A patent/CR20200476A/es unknown
- 2016-05-20 WO PCT/US2016/033452 patent/WO2016187508A2/en active Application Filing
- 2016-05-20 MY MYPI2017001689A patent/MY190974A/en unknown
- 2016-05-20 CR CR20230191A patent/CR20230191A/es unknown
- 2016-05-20 CN CN202211239802.9A patent/CN116196401A/zh active Pending
- 2016-05-20 JP JP2017560196A patent/JP6913032B2/ja active Active
- 2016-05-20 EP EP16732018.3A patent/EP3297660A2/en active Pending
- 2016-05-20 AU AU2016264623A patent/AU2016264623B2/en active Active
- 2016-05-20 TW TW105115840A patent/TWI806815B/zh active
- 2016-05-20 RU RU2017144467A patent/RU2733754C2/ru active
- 2016-05-20 IL IL302102A patent/IL302102A/en unknown
- 2016-05-20 CN CN201680042436.4A patent/CN108025048B/zh active Active
- 2016-05-20 CR CR20170584A patent/CR20170584A/es unknown
- 2016-05-20 MX MX2017014700A patent/MX2017014700A/es unknown
- 2016-05-20 US US15/575,328 patent/US10835585B2/en active Active
- 2016-05-20 IL IL255769A patent/IL255769B2/en unknown
- 2016-05-20 TW TW112105056A patent/TW202346325A/zh unknown
- 2016-05-20 IL IL294183A patent/IL294183B2/en unknown
- 2016-05-20 KR KR1020177036611A patent/KR20180010229A/ko not_active Application Discontinuation
- 2016-05-20 CA CA2986235A patent/CA2986235A1/en active Pending
-
2017
- 2017-11-16 MX MX2023005122A patent/MX2023005122A/es unknown
- 2017-11-20 CL CL2017002945A patent/CL2017002945A1/es unknown
- 2017-12-13 CO CONC2017/0012835A patent/CO2017012835A2/es unknown
- 2017-12-15 PH PH12017502321A patent/PH12017502321A1/en unknown
- 2017-12-20 EC ECIEPI201784137A patent/ECSP17084137A/es unknown
-
2018
- 2018-08-15 HK HK18110507.5A patent/HK1251148A1/zh unknown
- 2018-09-07 HK HK18111576.9A patent/HK1252267A1/zh unknown
-
2020
- 2020-04-27 US US16/859,252 patent/US20200368337A1/en active Pending
-
2021
- 2021-07-09 JP JP2021114423A patent/JP7282834B2/ja active Active
-
2022
- 2022-09-28 AU AU2022241521A patent/AU2022241521A1/en active Pending
-
2023
- 2023-05-17 JP JP2023081513A patent/JP2023103405A/ja active Pending
- 2023-08-16 CL CL2023002421A patent/CL2023002421A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023005122A (es) | Neoantigenos compartidos. | |
MX2022005060A (es) | Novedosos peptidos y combinaciones de peptidos para usarse en la inmunoterapia contra el cancer de pulmon, incluido el cancer de pulmon no microcitico (nsclc) y otros canceres. | |
PH12017500484A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers | |
EA201792242A1 (ru) | Новые пептиды и комбинации пептидов и их каркасы для применения в иммунотерапии колоректальной карциномы (крк) и других видов рака | |
AU2022205209B2 (en) | Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | |
MX2018005374A (es) | Nuevos peptidos y combinacion de peptidos para el uso en la inmunoterapia contra varios tipos de cancer. | |
MX2018004140A (es) | Peptidos y combinacion de peptidos para usarse en la inmunoterapia contra el cancer pulmonar microcelular y otros tipos de cancer. | |
EA201791853A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака поджелудочной железы и других видов рака | |
EA201891699A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей | |
PH12020500051A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers | |
MY196837A (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
MY190083A (en) | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers | |
MX2020011793A (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer. | |
PH12018500665A1 (en) | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |